Pancreatic cancer remains one of oncology's most formidable challenges, with five-year survival rates below 12% and limited treatment options once first-line therapies fail. The emergence of targeted therapies that can meaningfully extend survival in this population represents a potential watershed moment for patients facing one of medicine's most dire diagnoses. Clinical trial results demonstrate that daraxonrasib, a selective KRAS G12C inhibitor, delivered superior overall survival compared to standard chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma harboring this specific mutation. The targeted agent achieved a statistically significant improvement in median survival duration, marking a notable advance for a cancer type where therapeutic progress has been historically elusive. This finding builds on the broader revolution in KRAS-targeted therapy that has transformed treatment paradigms across multiple solid tumor types over the past several years. However, the KRAS G12C mutation occurs in only a subset of pancreatic cancer patients—approximately 1-2% of cases—limiting the immediate applicability of this approach. The trial's design focused on a biomarker-selected population, reflecting modern precision medicine principles but also highlighting the challenge of developing broadly effective treatments for pancreatic cancer's diverse molecular landscape. While these results represent genuine progress, they underscore the ongoing need for therapeutic advances that can benefit the majority of pancreatic cancer patients who lack targetable KRAS mutations. The data suggests that for the specific subset with KRAS G12C alterations, precision-targeted therapy may offer meaningful clinical benefit over conventional cytotoxic approaches in the relapsed setting.